Algeria vs Belarus: HIV/AIDS deaths averted by antiretroviral therapy
Algeria
1,007 deaths
in 2024
Belarus
1,203 deaths
in 2022
Algeria rank
73rd
Belarus rank
71st
HIV/AIDS deaths averted by antiretroviral therapy over time
- Algeria
- Belarus
How they compare
Belarus currently reports 1,203 deaths against 1,007 deaths in Algeria, a difference of 196 deaths.
That makes Belarus's figure about 1.2 times Algeria's.
The two have swapped places 2 times across 33 shared years of data; in 1990 it was Belarus ahead.
Algeria ranks 73rd and Belarus ranks 71st of 157 countries.
Across the 4 decades both report, Algeria averaged higher in 2 and Belarus in 2.
Head to head by decade
| Decade | Algeria | Belarus | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 4.15 deaths | 0 deaths | 4.15 deaths | Algeria |
| 2000s | 78.66 deaths | 70.2 deaths | 8.46 deaths | Algeria |
| 2010s | 458.68 deaths | 703.4 deaths | 244.72 deaths | Belarus |
| 2020s | 848.41 deaths | 1,184 deaths | 335.25 deaths | Belarus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Algeria or Belarus?
- Belarus, at 1,203 deaths against 1,007 deaths in Algeria as of 2022.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Algeria and Belarus?
- 196 deaths, with Belarus ahead.
- How many years of comparable data are there for Algeria and Belarus?
- 33 years are reported by both, from 1990 to 2022.
- How do Algeria and Belarus rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Algeria ranks 73rd and Belarus ranks 71st of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.